LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

POC Tests Represent Significant Share of World IVD Market

By LabMedica International staff writers
Posted on 25 Jan 2011
Print article
The market for point-of-care (POC) tests has almost doubled in size from 2003 to 2009. With the ability to help reduce healthcare costs while simultaneously improving patient care, point-of-care (POC) tests represent a significant and growing share of the world in vitro diagnostics (IVD) market.

The growth in POC sales, which is projected to increase by 6% annually through 2014, is largely related to significant increases in glucose self-testing of diabetics, and to various professional test segments including critical care and cardiac markers. Other contributing factors include the globalization of infectious diseases with the associated public health issues, and the need to monitor an increasingly larger group of people with chronic diseases such as cardiovascular disease, arthritis, and cancer.

In a new report, Kalorama Information (Rockville, MD, USA), a healthcare market research publisher, valued the market for combined over the counter (OTC) and professional applications of POC testing at US$13.3 billion worldwide in 2009.

Although POC tests (with the exception of the diabetes segment) have not achieved the 15% to 20% market growth predicted in the late 1990s, they have made a significant contribution to patient care. The total POC testing market has increased its market share in the United States and Europe from 25% of the IVD market in 2003 to 30% in 2009.

"As the largest single market for IVD and POC products, the U.S. has an enormous impact on how the rapid test industry develops," says Shara Rosen, Kalorama Information's lead diagnostics analyst and author of the report. "Managed care's obsession with cost reductions is pushing the need for decentralized testing in the home, at the bedside, and in the physician's office."

A different set of companies is active in each sub-segment of the highly diversified market for POC tests. More than 70 companies are active in POC markets, but with successive rounds of market consolidation and the emergence of Alere (Waltham, MA. USA), formerly Inverness Medical Innovations, as a major POC vendor, Kalorama estimates that 27 companies held 94% of the world market for POC tests in 2009.

Including details of the technologies and trends in decentralized testing, Kalorama Information's report specially focuses on the economics of rapid test use in physicians' offices, hospital critical care units, and emergency medicine and how it will impact healthcare.
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

Related Links:

Kalorama Information
Alere


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more